Lucas G. Hill, Pharm.D., FCCP

Dr. Lucas Hill smiling in an outdoor setting

Research Scientist, Pharmacy Addictions Research & Medicine Program

Adjunct Associate Professor of Pharmacy Practice

Dr. Hill is a research scientist in the Pharmacy Addictions Research and Medicine (PhARM) Program and an Adjunct Associate Professor of Pharmacy Practice at The University of Texas at Austin College of Pharmacy. He is dedicated to addressing substance use challenges through community-engaged research and workforce development. Dr. Hill's primary research focus is identifying, exploring, and addressing gaps in pharmacy implementation of evidence-based substance use services. He also works to advance the spectrum of substance use care through service on the AMERSA Board of Directors and the JACCP Editorial Board. Dr. Hill has been recognized with several prestigious national honors, including the ACCP New Educator Award and the APhA Generation Rx Award of Excellence.

National

  • American College of Clinical Pharmacy: Fellow (2023)
  • American College of Clinical Pharmacy: New Educator Award (2021)
  • American College of Clinical Pharmacy AmCare PRN: Outstanding Paper of the Year (2021)
  • American Pharmacists Association: Generation Rx Award of Excellence (2020)
  • American College of Clinical Pharmacy AmCare PRN: Outstanding Paper of the Year (2019)
  • American Society of Health-System Pharmacists: CEO’s Award for Courageous Service (2018)
  • Phi Lambda Sigma Pharmacy Leadership Society: Faculty Inductee (2017)

Regional

  • Austin Under 40 Awards: Finalist in Medicine & Healthcare (2021)
  • Austin Under 40 Awards: Finalist in Medicine & Healthcare (2020)
  • Texas Pharmacy Association: Generation Rx Champion Award (2018)

Local

  • UT College of Pharmacy: 10 Most Impactful Faculty (2022)
  • UT College of Pharmacy: Outstanding Faculty Advisor (2019)
  • UT School of Undergraduate Studies: Distinguished University Lecturer (2018)
  • UT College of Pharmacy: 10 Most Impactful Faculty (2018)
  • UT College of Pharmacy: William Arlyn Kloesel Outstanding APPE Preceptor (2017)
  • UT College of Pharmacy: ATW Regional Outstanding APPE Preceptor (2017)
  • UT College of Pharmacy: Outstanding IPPE Preceptor (2017)
  • UT College of Pharmacy: Phi Lambda Sigma Pharmacy Leadership Society (2017)

Fellowships

  • UT College of Pharmacy: Fellow of the Eckerd Professorship (2024)
  • UT College of Pharmacy: Bergen Brunswig Corporation Centennial Fellow (2021–2024)
  • UT College of Pharmacy: Alumni Centennial Fellow – Advisor (2019–2020)
  • UT College of Pharmacy: Alumni Centennial Fellow – Preceptor (2017–2018)

See CV for complete list

Centers of Excellence for Opioid Use Disorder: Hepatitis C Virus Technical Assistance ($150,000)

  • Role: Principal Investigator
  • Sponsor: Pennsylvania Department of Human Services
  • Funding Period: 5/1/2026–11/30/2027 [role ended 9/11/2026]

Physical Health Centers of Excellence Auditing Standardization ($560,000)

  • Role: Principal Investigator
  • Sponsor: Pennsylvania’s Medicaid Managed Care Organizations
  • Funding Period: 2/1/2026–1/31/2028 [role ended 9/11/2026]

Centers of Excellence for Opioid Use Disorder: Care Management Technical Assistance ($2,192,927)

  • Role: Principal Investigator
  • Sponsor: Pennsylvania Department of Human Services
  • Funding Period: 7/1/2025–6/30/2027 [role ended 9/11/2026]

Project Lifeline National Rollout ($900,000)

  • Role: Principal Investigator
  • Sponsor: National Association of Chain Drug Stores Foundation
  • Funding Period: 1/1/2023–6/30/2027 [role began 12/1/2024 and ended 9/11/2026]

Improving Opioid Stewardship and Access to Harm Reduction Services through Allegheny County Community Pharmacies ($420,360)

  • Role / Effort: Co-Investigator / 4%
  • PI: Joni Carroll, University of Pittsburgh
  • Sponsor: Allegheny County
  • Funding Period: 4/1/2025–6/30/2027 [role ended 9/11/2026]

Centers of Excellence for Opioid Use Disorder: Care Management Technical Assistance ($1,080,018)

  • Role: Co-Principal Investigator
  • Sponsor: Pennsylvania Department of Human Services
  • Funding Period: 7/1/2024–6/30/2025 [role began 12/1/2024]

Creation of a Multi-Stakeholder Practice Guideline to Improve Access to Medications for Opioid Use Disorder in Community Pharmacies ($572,278)

  • Role / Amount: Co-Investigator / $28,872
  • PI: Tyler Varisco, University of Houston
  • Sponsor: Foundation for Opioid Response Efforts
  • Funding Period: 4/1/2023–3/31/2025

Texas Targeted Opioid Response – Educational Task Force ($4,942,560)

  • Role: Principal Investigator
  • Sponsor: Substance Abuse and Mental Health Services Administration
  • Funding Period: 9/01/2024–8/31/2026 [role ended 11/30/2024]

Empowering Clinicians to Prevent Opioid-Related Harms and Treat Opioid Use Disorder: An Academic Detailing Intervention for Prescribers in Austin, Texas ($375,000)

  • Role: Principal Investigator
  • Sponsor: Substance Abuse and Mental Health Services Administration
  • Funding Period: 9/30/2023–01/31/2026 [role ended 11/30/2024]

Texas Targeted Opioid Response – PhARM Program Special Projects ($34,045,430)

  • Role: Principal Investigator
  • Sponsor: Substance Abuse and Mental Health Services Administration
  • Funding Period: 5/1/2019–8/31/2024

Overdose Prevention Education Curriculum and Toolkit ($120,000)

  • Role: Principal Investigator
  • Sponsor: Texas Education Agency
  • Funding Period: 5/15/2024–8/31/2024

A Statewide Needs Assessment to Identify Opportunities to Improve Access to Medications for Opioid Use Disorder through Mobile Service Provision ($162,579)

  • Role / Amount: Co-Investigator / $30,000
  • PI: Jennifer Sharpe Potter, UT Health San Antonio
  • Sponsor: Substance Abuse and Mental Health Services Administration
  • Funding Period: 6/1/2022–8/31/2022

Texas Targeted Opioid Response – Operation Naloxone ($2,587,149)

  • Role: Principal Investigator
  • Sponsor: Substance Abuse and Mental Health Services Administration
  • Funding Period: 7/1/2017–4/30/2019

See CV for complete list

Television & Radio Interviews

Print Interviews

See CV for complete list

Book Chapters

Hill LG, Loera LJ. (2026). Chapter 89: Substance use disorders I: Opioids, sedatives, stimulants, hallucinogens, and cannabis. In: Haines ST, Nolin TD, Ellingrod VL, Posey LM, Cocohoba J, Holle L. DiPiro’s Pharmacotherapy: A Pathophysiologic Approach, 13th Edition. New York, NY: McGraw Hill.

Loera LJ, Hill LG. (2026). Chapter e88: Introduction to substance use disorders. In: Haines ST, Nolin TD, Ellingrod VL, Posey LM, Cocohoba J, Holle L. DiPiro’s Pharmacotherapy: A Pathophysiologic Approach, 13th Edition. New York, NY: McGraw Hill.

Peckham AM, Hill LG. (2021). Harm reduction for people who inject drugs: A life-saving opportunity. In: Covvey JR, Arya V, DiPietro Mager NA, Gilman NV, Herring M, Lukas S, Ochs L, Waddington L, eds. Public Health in Pharmacy Practice: A Casebook. 2nd ed. Geneseo, NY: Milne Open Textbooks.

Hill LG, Jacobson AN. (2019). Opioid harm reduction. In: Dixon DL, Harris IM, eds. Ambulatory Care Self-Assessment Program: Neurologic Care and Pain Management. Lenexa, KS: American College of Clinical Pharmacy.

Hill LG. (2018). Harm reduction approaches to opioids. In: Schepis TS, ed. The Prescription Drug Abuse Epidemic: Incidence, Prevention, Treatment, and Policy. Santa Barbara, CA: ABC-CLIO, LLC.
 

Peer-Reviewed Journal Articles

Erickson E, Kane H, Garcia SA, Hinnant L, Rabre A, Hill LG, Loera LJ, Temblador A, *Duncan Cance J. (2026). “Leaving the decision step to me:” School naloxone policies developed and implemented by district and school nurses. Subst Use Addctn J. DOI: 10.1177/29767342261448407.

Sisson LN, Rousch RS, Hill LG, Zagorski CM, Triece T, Rouhani S, Owczarzak J, Sherman SG, *Schneider KE. (2026). “If you've ever experienced it, you’d feel differently”: Exploring willingness and skepticism towards using higher dose naloxone products among people who use drugs in Maryland. Addiction. 121(9):2494-2503. DOI: 10.1111/add.70447.

Torrez SB, Evoy KE, Reveles KR, Hill LG, Lawson KE, *Loera LJ. (2026). Increasing buprenorphine and naloxone access in Texas community pharmacies through an academic detailing intervention. Subst Use Addctn J. 47(3):762-771. DOI: 10.1177/29767342261422061.

Hendy LE, Hill LG, Olguin A, Barrett E, Jimes C, Coffey MJ, *Lira MC. (2025). Pharmacy barriers to receiving buprenorphine among patients in telemedicine addiction treatment. JAMA Netw Open. 8(8): e2527418. DOI: 10.1001/jamanetworkopen.2025.27418.

Varisco TJ, Thornton D, Hussain T, Fish H, Bolin J, Dadiomov D, Essien EJ, Wanat MA, Ginsburg D, Waggener J, Bratberg J, DiPaula B, *Hill LG. (2025). Addressing wholesale distributor barriers to buprenorphine access: Consensus recommendations from the PhARM-OUD Expert Panel. Drug Alcohol Depend Rep. 16:100360. DOI: 10.1016/j.dadr.2025.100360.

*Hill LG. (2025). Redefining opioid stewardship. J Am Coll Clin Pharm. 8:168-170. DOI: 10.1002/jac5.70002.

Loera LJ, Lines J, Mayberry S, Hilzendager S, Ferguson A, *Hill LG. (2025). Over-the-counter naloxone and non-prescription syringe availability in community pharmacies. JAMA Netw Open. 8(2):e2458095. DOI: 10.1001/jamanetworkopen.2024.58095. AACP Public Health SIG Best Poster Award.

*Varisco TJ, Fish H, Bolin J, Dadiomov D, Hill LG, Essien E, Wanat MA, Ginsburg D, Waggener J, Thornton D. (2024). The pharmacy access to resources and medication for opioid use disorder (PhARM-OUD) guideline: A joint consensus practice guideline from the National Association of Boards of Pharmacy and the National Community Pharmacists Association. DOI: 10.52713/PhARM-OUD.

*Russell E, Hawk M, Neale J, Bennet A, Davis C, Hill LG, Winograd R, Kestner L, Lieberman A, Bell A, Santamour T, Murray S, Schneider KE, Walley AY, Jones TS. (2024). A call for compassionate overdose response as the standard of care. Int J Drug Policy. 133:104587. DOI: 10.1016/j.drugpo.2024.104587.

Light AE, Green TC, Freeman PR, Burns AL, Sanaty Zadeh P, *Hill LG. (2024). Relationships between stigma, risk tolerance, and buprenorphine dispensing intentions among community-based pharmacists: Results from a national sample. Subst Use Addctn J. 45(2):211-221. DOI: 10.1177/29767342231215178.

Jarrett JB, Bratberg JP, Burns AL, Cochran G, DiPaula BA, Dopp AL, Elmes A, Green TC, Hill LG, Homsted F, Hsia SL, Matthews ML, Ghitza UE, Wu L, *Bart G. (2023). Research priorities for expansion of opioid use disorder treatment in the community pharmacy. Subst Abus. 44(4):264-276. DOI: 10.1177/08897077231203849.

Zagorski CM, Hosey R, Moraff C, Ferguson A, Figgatt M, Aronowitz S, Stahl N, Hill LG, McElligott Z, *Dasgupta N. (2023). Reducing the harms of xylazine: Clinical approaches, research deficits, and public health context. Harm Reduct J. 20:141. DOI: 10.1186/s12954-023-00879-7.

Zalmai R, *Hill LG, Loera LJ, Mosgrove Q, Brown CM. (2023). Community pharmacists’ attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder. J Am Pharm Assoc. 63(5):1558-1565. DOI: 10.1016/j.japh.2023.06.010.

*Ostrach B, Hill LG, Carpenter D, Pollini R. (2023). Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility. J Am Pharm Assoc. 63(4):1044-1048. DOI: 10.1016/j.japh.2023.04.029.

*Varisco TJ, Wanat M, Hill LG, Thornton D. (2023). The impact of the Mainstreaming Addiction Treatment Act and associated legislative action on pharmacy practice. J Am Pharm Assoc. 63(4):1039-1043. DOI: 10.1016/j.japh.2023.04.016.

*Hill LG, Light AE, Green TC, Burns AL, Sanaty Zadeh P, Freeman PR. (2023). Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists. J Am Pharm Assoc. 63(1):252-260. DOI: 10.1016/j.japh.2022.08.017.

Loera LJ, *Hill LG, Zagorski CM, Jermain ML, Tirado CF. (2023). Description and evaluation of a pilot advanced pharmacy practice experience in addiction medicine. Am J Pharm Educ. 87(1):8926. DOI: 10.5688/ajpe8926.

Lai RK, Friedson KE, Reveles KR, Bhakta K, Gonzales G, Hill LG, *Evoy KE. (2022). Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review. J Am Pharm Assoc. 62(6):1725-1740. DOI: 10.1016/j.japh.2022.07.008.

*Hill LG, Loera LJ, Torrez SB, Puzantian T, Evoy KE, Ventricelli DJ, Eukel H, Peckham AM, Chen C, Ganetsky V, Yeung M, Zagorski CM, Reveles KR. (2022). Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. Drug Alcohol Depend. 237:109518. DOI: 10.1016/j.drugalcdep.2022.109518.

Gugala E, Briggs O, Moczygemba LR, Brown CM, *Hill LG. (2022). Opioid harm reduction: A scoping review of physician and system-level gaps in knowledge, education, and practice. Subst Abus. 43(1):972-987. DOI: 10.1080/08897077.2022.2060423.

*Hill LG, Zagorski CM, Loera LJ. (2022). Increasingly powerful opioid antagonists are not necessary. Int J Drug Policy. 99:103457. DOI: 10.1016/j.drugpo.2021.103457.

*Hill LG, Loera LJ, Evoy KE, Torrez SB, Renfro ML, Zagorski CM, Perez JC, Jones SM, Reveles KR. (2021). Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. Addiction. 116(6):1505-1511. DOI: 10.1111/ADD.15314. ACCP Ambulatory Care PRN Outstanding Paper of the Year.

*Peckham AM, Ball J, Colvard MD, Dadiomov D, Hill LG, Nichols SD, Tallian K, Ventricelli DJ, Tran TH. (2021). Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic. Am J Health Syst Pharm. 78(7):612-618. DOI: 10.1093/ajhp/zxab003. Innovation in Pharmacy Practice Award – Finalist.

*Evoy KE, Hill LG, Davis CS. (2021). Considering the potential benefits of over-the-counter naloxone. Integr Pharm Res Pract. 10:13-21. DOI: 10.2147/iprp.S244709.

*Coon SA, Hill LG, Hutchison RW, Arnold LM, Jarrett JB, Ottney AR, Oung AB, Painter NA, Smith MA, Stranges PM, Tran TH, McFee Winans AR, Bratberg JP. (2020). Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks for the American College of Clinical Pharmacy. J Am Coll Clin Pharm. 3(8):1493-1513. DOI: 10.1002/jac5.1331.

*Tran T, Ball J, Bratberg JP, DeSimone EM, Franko TS, Hill LG, Koh-Knox Sharp CP, Palombi L, Ventricelli D, Farrell D, Gandhi N, Moore T. (2020). Report of the 2020 special committee on substance use and pharmacy education. Am J Pharm Educ. 84(11):8421. DOI: 10.5688/ajpe8421.

*Renfro ML, Moczygemba LR, Baumgartner J, Baumgart G, Hill LG. (2020). Opioid-related education provided by continuing education divisions at US pharmacy schools. Am J Pharm Educ. 84(10):8001. DOI: 10.5688/ajpe8001.

*Zagorski CM, Myslinski JM, Hill LG. (2020). Isotonitazene as a contaminant of concern in the illegal opioid supply: A practical synthesis and cost perspective. Int J Drug Policy. 86:102939. DOI: 10.1016/j.drugpo.2020.102939.

*Hill LG, Holleran Steiker LK, Mazin L, Kinzly ML. (2020). Implementation of a collaborative model for opioid overdose prevention on campus. J Am Coll Health. 68(3):223-226. DOI: 10.1080/07448481.2018.1549049.

*Evoy KE, Groff L, Hill LG, Godinez W, Gandhi R, Reveles KR. (2020). Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas. J Am Pharm Assoc. 60:81-86. DOI: 10.1016/j.japh.2019.09.007.

*Hill LG, Evoy KE, Reveles KR. (2019). Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction. J Am Pharm Assoc. 59(6):779-782. DOI: 10.1016/j.japh.2019.06.019.

*Hill LG, Reveles KR, Evoy KE. (2019). State-level approaches to expanding pharmacists’ authority to dispense naloxone may affect accessibility. JAMA Intern Med. 179(10):1442-1443. DOI: 10.1001/jamainternmed.2019.3653.

*Evoy KE, Hill LG, Groff L, Mazin L, Carlson CC, Reveles KR. (2018). Naloxone accessibility without a prescriber encounter under standing orders at community pharmacy chains in Texas. JAMA. 320(18):1934-1937. DOI: 10.1001/jama.2018.15892. ACCP Ambulatory Care PRN Outstanding Paper of the Year.

*Hill LG, Sanchez JP, Laguado SA, Lawson KA. (2018). Operation Naloxone: Overdose prevention service learning for student pharmacists. Curr Pharm Teach Learn. 10(10):1348-1353. DOI: 10.1016/j.cptl.2018.07.010.

*Han JK, Hill LG, Koenig ME, Das N. (2017). Naloxone counseling for harm reduction and patient engagement. Fam Med. 49(9):730-733.

Contact Information

CV

Google Scholar

LinkedIn

ORCID

PhARM Program

PubMed

ResearchGate

Texas Opioid Training Initiative